Business Plan

Pending Patent PCT/MX 2003/000105

“Magnetic Resonance Device”

2008

I. EXECUTIVE SUMMARY.

Technological proposal referring to the apparatus and corresponding method which integrates a quantified diagnosis and a novel and highly specialized therapy on the basis of NMR technology

The present technological proposal consists in increasing the capacities of NMR devices through the incorporation of additional hardware and software elements which permit the provision of quantified images for a better diagnosis of diseases. Afterwards, the internal radiation parameters can be manipulated in order to provide a more specialized, more effective and safer therapy than the currently available.

Even if the technological proposal may be applied for the treatment of many diseases, we have been concentrating on its use for Cancer and HIV/AIDS.

1. Cancer

Currently, there are many diagnostic methods and above all with the aid of imaging techniques (Conventional ultrasound and third dimension, conventional X-Rays, computerized axial tomography and NMR). These techniques are used by physicians in order to diagnose Cancer and other diseases. However, nowadays only an exact diagnosis is possible by performing a biopsy, which is an invasive procedure and cannot be applied to patients in every case due to its risks.

Cancer patients are currently treated with different types of therapies which are fundamentally based on ionizing radiations, chemotherapies on the basis of cytostatic and non-cytostatic agents and surgeries. These therapy types are normally combined with each other in order to be more effective.

Our scientific proposal consists in the use of a modified NMR technology. These modifications permit a quantified diagnosis and a highly specialized therapy with a selectivity index towards the damaged cells, on both a macroscopic and a microscopic level, which has no precedents in the current state-of-the-art.

2. HIV/Aids

Currently, HIV/AIDS patients can only dispose of preventive treatments and therapies on the basis of medicaments (vaccines, interferons, inferons, monoclonal antibodies etc.) which merely “decelerate” the development of the disease and a part of its harmful side effects without effectively avoiding them.

Within this scientific proposal, NMR devices are used for treatment applying radiation to the affected area, offering a high potential of selectivity indexes and avoiding harmful side effects.

The targeted market has a significant size and possesses a large potential for growth as described below.

In 2002, about 120 million diagnostic studies with NMR equipments were performed generating revenues of more than US$ 2.8 billion. The market of medical diagnoses has shown a strong growth for years and it is expected to continue in the same path in the foreseeable future.

The market of Nuclear Magnetic Resonance Systems (NMR) sold 1,055 equipments for an amount of US$ 1.46 billion in 2002. It is expected that in 2010, the revenues will surpass US$ 4.0 billion.

These figures, which are already impressive, are calculated considering NMR equipments which exclusively enable an “empirical” diagnosis. Consequently, one can imagine the market’s potential of improved NMR systems capable of delivering quantified diagnoses as well as personalized therapies. By this means, a total cure for Cancer and HIV/AIDS can be guaranteed with the aid of the present scientific proposal.

Only considering the implementation of the therapy mode without taking into account the improvements of the diagnosis mode, the therapy would be applied to 500,000 Cancer patients (estimated number of patients who are receiving radiation therapies). Only regarding Cancer, the present scientific proposal would generate revenues of more than US$ 11 billion per year.

In a similar manner, the scientific proposal annually applied to only 500,000 of the more than 40 million HIV/AIDS patients, considering a per patient cost of US$ 20,000 (which is equal to the annual cost of the currently used treatment which does not cure the patient), would generate revenues of US$ 10 billion per year.

MRI-DT, S.A. de C.V. is a small company founded in order to perform the R&D workings related to the pending patent PCT/MX 2003/000105, “Magnetic Resonance Device” which refers to the apparatus and corresponding method integrating a quantified diagnosis and a novel specialized therapy by using an NMR device.

The investment required for R&D Phase II (4 semesters) is **US$ 3,629,650.00** divided as follows:



The principal objective of this novel scientific proposal is capacitating NMR devices for:

1. - a quantified diagnosis.

2. - a selective and specialized therapy.

We are sure that the main manufacturers of imaging equipments (General Electric, Siemens, Toshiba, Hitachi, Philips, Varian, etc.) are able to cost-effectively implement the present scientific proposal in their product lines.

In the following, we present some of the investment criteria regarding the proposal:

a) Excellent risk/reward relationship; taking into consideration the funds predicted on the basis of the market potential for this type(s) of technology and disease. The benefits will be perceivable at short notice.

b) Patent protection rights; the present scientific proposal has the status of a pending patent and is in the so called national phases in the countries which possess the main markets regarding both this type of technology as well as these diseases.

c) Short term partial results; delivery of quantified diagnosis capability for NMR systems is expected at the end of the 2nd semester of Phase II (in which the quantified diagnosis is obtained). The value of the present scientific proposal would significantly increase and we expect to start negotiating licensing agreements with NMR equipment manufacturers at this stage and with radiotherapy manufacturers as a second option.

d) Application to humans already a reality; it is very important to know that non-ionizing electromagnetic radiation is applied during both diagnoses and therapies. Therefore, we do not expect any problems on the part of approving authorities, since the inherited benefits are obvious.

e) Significant relevance to humanity; this technological proposal is aimed at very common diseases like Cancer and HIV/AIDS. Due to the rapid implementation times for the R&D workings, we expect a rapid introduction on the health market. Since the costs of the scientific proposal are significantly low, there is also a very attractive cost-benefit-ratio.